Rekvina Labs

Which are the latest news on Rekvina Labs?

Why is Rekvina Labs Ltd falling/rising?

As of 12-Jul, Rekvina Labs Ltd's stock price is Rs 35.00, reflecting a 2.78% decrease and underperforming its sector. The decline is attributed to reduced investor participation and bearish trading patterns, despite being above some moving averages.

As of 12-Jul, Rekvina Labs Ltd's stock price is falling, currently at Rs 35.00, which reflects a decrease of Rs 1.00 or 2.78%. The stock has underperformed its sector by 3.01% today and opened with a loss of 2.78%. It reached an intraday low of Rs 35, indicating a lack of upward momentum. Additionally, the stock has shown erratic trading patterns, having not traded on 2 out of the last 20 days. <BR><BR>Investor participation has also declined significantly, with a delivery volume of 198 on 08-Jul, which is down by 85.83% compared to the 5-day average delivery volume. This drop in trading activity suggests a lack of interest from investors, contributing to the stock's downward trend. While the stock is trading higher than its 5-day, 100-day, and 200-day moving averages, it is lower than the 20-day and 50-day moving averages, further indicating a bearish sentiment. Overall, these factors collectively explain the decline in Rekvina Labs Ltd's stock price.

Who are in the management team of Rekvina Labs?

The management team of Rekvina Labs consists of Amit Shah (Director), Mukesh Shah (Director), Vibha Mukesh Shah (Additional Director), and Mahendra Shantilal Dalal (Additional Director).

The management team of Rekvina Labs includes the following individuals:<BR><BR>1. Amit Shah - Director<BR>2. Mukesh Shah - Director<BR>3. Vibha Mukesh Shah - Additional Director<BR>4. Mahendra Shantilal Dalal - Additional Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Rekvina Labs?

Rekvina Labs' peers include Sun Pharma, Divi's Lab, Torrent Pharma, Cipla, Dr Reddy's Labs, Lupin, Cresanto Global, Sang Froid Labs, and Vardhaman Labs. Sun Pharma and Lupin show excellent growth and management quality, while Torrent Pharma has the highest 1-year return at 42.88%, and Cipla has the lowest at -8.95%.

Peers: The peers of Rekvina Labs are Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Dr Reddy's Labs, Lupin, Cresanto Global, Sang Froid Labs, and Vardhaman Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Dr Reddy's Labs, and Lupin, while the rest do not qualify. Growth is excellent at Sun Pharma.Inds. and Lupin, good at Dr Reddy's Labs, average at Torrent Pharma, and below average at Divi's Lab. and Cipla, while the rest do not qualify. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, good at Torrent Pharma and Lupin, while the rest do not qualify.<BR><BR>Return Snapshot: Torrent Pharma has the highest 1-year return at 42.88%, while Cipla has the lowest at -8.95%, and Rekvina Labs does not have a 1-year return to compare. Additionally, Cipla and Dr Reddy's Labs have negative six-month returns.

What does Rekvina Labs do?

Rekvina Labs Ltd is an integrated Indian pharmaceutical company specializing in pharmaceutical formulations and contract research and manufacturing services, with a market cap of INR 24 Cr and reported net sales of 1 Cr for the quarter ending March 2026. The company has been operational since 1988 and has evolved significantly in the pharmaceutical industry.

Overview:<BR>Rekvina Labs Ltd is an integrated Indian pharmaceutical company operating in the Micro Cap category, specializing in the production of pharmaceutical formulations and providing contract research and manufacturing services.<BR><BR>History:<BR>Incorporated on 1st November 1988, Rekvina Labs has evolved from a small domestic company in the mid-1980s to a significant player in the pharmaceutical industry, with reported sales exceeding Rs 20 Crore. The latest quarterly results indicate net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 24 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.22<BR>- Return on Equity: 25.00%<BR>- Price to Book: -24.48<BR><BR>Contact Details:<BR>Address: 328 Paradise Complex, Sayajigunj Vadodara Gujarat : 390005 <BR>Tel: 91-265-2362966 <BR>Email: rekvina@gmail.com <BR>Website: http://www.rekvinalaboratories.com

Are Rekvina Labs Ltd latest results good or bad?

Rekvina Labs Ltd's latest results show mixed performance, with a 105.71% revenue increase and a 50% reduction in net loss, but ongoing challenges like negative book value and persistent losses raise concerns about its financial stability and profitability. Overall, the outlook remains cautious despite some positive metrics.

Rekvina Labs Ltd's latest results present a mixed picture. On one hand, there has been a notable improvement in certain metrics; for instance, the company reported a revenue of ₹0.72 crores in Q4 FY26, which is a significant sequential growth of 105.71% compared to the previous quarter. Additionally, the net loss has improved by 50% quarter-over-quarter, now standing at ₹0.06 crores. The operating margin has also shown improvement, moving from -34.29% to -8.33%.<BR><BR>However, despite these positive changes, the company continues to face significant challenges. It has a negative book value, meaning its liabilities exceed its assets, which raises serious concerns about its financial health. The persistent net losses and lack of a clear path to profitability indicate ongoing operational difficulties. Moreover, the stock has experienced considerable volatility and has declined significantly over the past month, reflecting growing investor skepticism.<BR><BR>Overall, while there are signs of improvement in revenue and loss reduction, the fundamental issues regarding profitability and financial stability remain a concern, leading to a cautious outlook on the company's performance.

Should I buy, sell or hold Rekvina Labs Ltd?

When is the next results date for Rekvina Labs Ltd?

The next results date for Rekvina Labs Ltd is 21 May 2026.

The next results date for Rekvina Labs Ltd is scheduled for 21 May 2026.